Clinical utility of free drug monitoring

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 10, 2002, Pages 986-993

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Chinese medicines; Free drug concentration; Hypoalbuminemia; Liver disease; Uremia

Indexed keywords

ALBUMIN; AMIKACIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHINESE DRUG; DICLOXACILLIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; EPOXIDE; ETHOSUXIMIDE; FUROSEMIDE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; LIDOCAINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NON PRESCRIPTION DRUG; OXACILLIN; PENICILLIN DERIVATIVE; PHENYTOIN; PLASMA PROTEIN; PRIMIDONE; QUINIDINE; SALICYLIC ACID; TOBRAMYCIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ARTICLE; CHINESE MEDICINE; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG OVERDOSE; DRUG PROTEIN BINDING; HUMAN; HYPOALBUMINEMIA; IMMUNOASSAY; IMMUNOREACTIVITY; LEUKOPENIA; LIVER DISEASE; NEUROTOXICITY; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; UREMIA; BINDING COMPETITION; BLOOD; DRUG EFFECT; DRUG INTERACTION; LACRIMAL FLUID; METABOLISM; METHODOLOGY; REVIEW; SALIVA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BINDING, COMPETITIVE; BLOOD PROTEINS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; HYPOALBUMINEMIA; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS; SALIVA; TEARS; UREMIA;

EID: 0036432653     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.172     Document Type: Article

References (82)

1. Chan S, Gerson B. Free drug monitoring. Clinics Lab Med 1987; 7:279-87.
2. Klotz U, Antonin KH. Pharmacokinetics and bio-availability of sodium valproate. Clin Pharmacol Ther 1977; 21:736-43.
3. Meinardi H, Vander Kleijn E, Meijer JWA. Absorption and distribution of anti-epileptic drugs. Epilepsia 1982; 23:23-6.
4. Booker HE, Darcey B. Serum concentrations of free diphenylhydatoin and their relationship to clinical intoxication. Epilepsia 1973; 2:177-84.
5. Blum MR, Riegelman S, Becker CE. Altered protein binding of diphenylhydamtoin in uremic plasma. N Engl J Med 1972; 286:109.
6. Perucca E. Free level monitoring of antiepileptic drugs: clinical usefulness and case studies. Clin Pharmacokinetic 1984; 9(Suppl):71-8.
7. Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985; 151:193-216.
8. Soldin SJ. Free drug measurements when and why? An overview. Arch Pathol Lab Med 1999; 123:822-3.
9. Urien S, Albengres E, Tillement JP. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease. Int J Clin Pharmacol 1981; 19:319-25.
10. Bowdle TA, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28:486-92.
11. Marty JJ, Kilpatrick CJ, Moulds RFW. Intra-close variation in plasma protein binding of sodium valproate in epileptic patients. Br J Clin Pharmacol 1982; 14:399-404.
12. Gugler R, Von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinetic 1980; 5:67-83.
13. Chadwick DW. Concentration-effect relationship of valproic acid. Clin Pharmacokinetic 1985; 10:155-63.
14. Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient. Ann Pharmacother 1993; 27:32-5.
15. Haroldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother 2000; 34:183-7.
16. Lenn NJ, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992; 42:988-90.
17. Bauer LA, Davis R, Wilensky A, Raisys VA, Levy RH. Diurnal variation in valproic acid clearance. Clin Pharmacol Ther 1984; 35:505-9.
18. Bauer LA, Davis R, Wilensky A, Raisys VA, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly patients. Clin Pharmacol Ther 1985; 37:697-700.
19. Rapeport WG, Mendelow AD, French G, MacPherson P, Teasdale E, Agnew E, et al. Plasma protein binding and CSF concentration of valproic acid in man following acute oral dosing. Br J Clin Pharmacol 1983; 8:362-71.
20. Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984; 17:539-46.
21. Fedler C, Stewart MJ. Plasma total phenytoin: a possible misleading test in developing countries. Ther Drug Monit 1999; 21:155-60.
22. Dutkiewicz G, Wojcicki J, Garwronska-Szklarz B. The influence of hyperlipidemia on pharmacokinetics of free phenytoin. Neurochir Pol 1995; 29:203-11.
23. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1997; 313:75-9.
24. Naidu S, Moodley J, Botha J, McFadyen L. The efficacy of phenytoin in relation to serum levels in severe pre-eclampsia and eclampsia. Br J Obstet Gynaecol 1992; 99:881-6.
25. Sjoholm I, Kober A, Odar-Cederlof I, Borga O. Protein binding of drugs in uremia and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976; 25:1205-13.
26. McNamara PI, Lalka D, Gibaldi M. Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981; 98:730-40.
27. Reidenberg MM, Drayer DE. Alteration of drug protein binding in renal disease. Clin Pharmacokinetic 1984; 9 (Suppl 1):18-26.
28. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994; 105:602-4.
29. Zielmann S, Mielck F, Kahl R, KazmaierS, Sydow M, Kolk J, et al. A rational basis for the measurement of free phenytoin concentrations in critically ill trauma patients. Ther Drug Monit 1994; 16:139-44.
30. Burt M, Anderson D, Kloss J, Apple F. Evidence based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000; 46:1132-5.
31. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10,11-epoxide. Clin Pharmacokinetic 1986; 11:177198.
32. Froscher W, Burr W, Penin H, Vohl J, Bulau P, Kreiten K. Free level monitoring of carbamazepine and valproic acid: clinical significance. Clin Neuropharmacol 1985; 8:362-71.
33. Lesser RP, Pippenger CE, Luders H, Dinners DS. High dose monotherapy in treatment of intractable seizure. Neurology 1984; 34:707-11.
34. Al-Qudah AA, Hwang PA, Giesbrecht E, Soldin SJ. Contribution of 10,11-epoxide to neurotoxicity in epileptic children on polytherapy. Jordan Med J 1991; 25:171-7.
35. Potter JM, Donnelly A. Carbamazepine 10,11-epoxide in therapeutic drug monitoring. Ther Drug Monit 1998; 20:652-7.
36. Weber LT, Shipkova M, Armstrong VW, Wagner N, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13:759-68.
37. Perucca D, Hebdige S, Frigo GM, Gatti G, Lacchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28:779-89.
38. Monk A, Richens A. Effect of single dose sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther 1980; 27:89-95.
39. Fraser DG, Ludden TM, Evans RP, Sutherland EW. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 1980; 27:165-9.
40. Leonard RF, Rankin GO, Robinson DS, Melnic DE. Phenytoin-salicylate interactions. Clin Pharmacol Ther 1981; 29:56-60.
41. Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal anti-inflammatory drugs tolmetin, ibuprofen and naproxen in normal and uremic sera. Ther Drug Monit 1996; 18:97-9.
42. Datta P, Dasgupta A. Interactions between drugs and Asian medicine: displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicine Chan Su and Lu-Shen-Wan. Ther Drug Monit 2000; 22:155-9.
43. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol 2000; 38:245-53.
44. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL. Correlation and prediction of phenytoin using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001; 23:263-7.
45. Gulyassy PF, Jarrard E, Stanfel L. Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma. Adv Exp Med Biol 1987; 223:55-8.
46. Takamura N, Maruyama T, Otagiri M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia. Clin Chem 1997; 43:2274-80.
47. Dasgupta A, Malik S. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. Am J Nephrol 1994; 14:162-8.
48. Wong MC, Suite NDA, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol 1990; 47:640-2.
49. Burger D, Meenhorst PL, Mulder JW, Kraaijeveld CL, Koks CH, Bult A, et al. Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. Ther Drug Monit 1994; 16:616-20.
50. Dasgupta A, McLemore J. Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Ther Drug Monit 1998; 20:63-7.
51. Toler SM, Wilkerson MA, Porter WH, Smith AJ, Chandler MH. Severe phenytoin intoxication as a result of altered protein binding in AIDS. DICP 1990; 24:698-700.
52. Sandyk R. Phenytoin toxicity induced by interaction with ibuprofen. S Afr Med J 1982; 62:592.
53. Tsanaclis LM, Allen J, Perucca E, Routledge PA, Richens A. Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol 1984; 18:17-20.
54. Pospisil J, Perlik F. Binding parameters of phenytoin during monotherapy and polytherapy. Int J Clin Pharmacol Ther Toxicol 1992; 30:24-8.
55. Arimori K, Nanko M, Otagiri M, Uekama K. Effect of penicillins on binding of phenytoin to plasma proteins in vitro and in vivo. Biochem Drug Dispos 1984; 5:219-27.
56. Dasgupta A, Sperelakis A, Mason A, Dean R. Phenytoinoxacillin interactions in normal and uremic sera. Pharmacotherapy 1997; 17:375-8.
57. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin and sulfamethoxazole. Clin Chem 1991; 37:98-100.
58. Dasgupta A, Emerson L. Interaction of valproic acid with nonsteroidal anti-inflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit 1996; 18:654-9.
59. Blum RA, Schentag JJ, Gardner MJ, Wilner KD. The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. Br J Clin Pharmacol 1995; 39 (Suppl 1) 35S-38S.
60. Biddle D, Wells A, Dasgupta A. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors. Life Sci 2000; 66:143-51.
61. Dasgupta A, Thompson WC. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera. Ther Drug Monit 1995; 17:199-202.
62. Dasgupta A, Paul A, Wells A. Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am J Med Sci 2001; 322:204-8.
63. Rroutledge A, Stargel WW, Wagner GS, Shand DG. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Internal Med 1980; 93:701-4.
64. Barchowsky PA, Shand DG, Stargel WW, Wagner GS, Routledge A. On the role of alpha-1-acid glycoprotein in the lidocaine accumulation following myocardial infarction. Br J Clin Pharmacol 1982; 13:411-5.
65. Li JH, Xu JQ, Cao XM, Ni L, Li Y, Zhuang YY, Gong JB. Influence of the ORM 1phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta 2002; 317:85-92.
66. Kishore K, Raina A, Misra V, Jonas E. Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin. Ann Pharmacother 1993; 27:877-80.
67. Endo L, Bressolle F, Gomrni R, Bologna C, Sany J, Combe B. Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 1996: 18:128-34.
68. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva: an update. Clin Pharmacokinetic 1992; 23:365-79.
69. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples: focus on anticonvulsants. Clin Pharmacokinetic 1999; 36:453-70.
70. Press J, Berkovitch M, Laxer R, Giesbrecht E, Verjee Z, Silverman E, et al. Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic disease. Ther Drug Monit 1995; 17:247-50.
71. Nakajima M, Yamato S, Shimada K, Sato S, Kitagawa S, Honda A, et al. Assessment of drug concentrations in tears in therapeutic drug monitoring I: determination of valproic acid in tears by gas chromatography/mass spectrometry with EC/NCI mode. Ther Drug Monit 2000; 22:716-22.
72. Ujhelyi MR, Green PJ, Cummings DM, Roberts S, Vlasses PH, Zarowitz BJ. Determination of free serum digoxin concentration in digoxin toxic patients after administration of digoxin fab antibodies. Ther Drug Monit 1992; 14:147-54.
73. Valdes R, Jortani SA. Monitoring of unbound digoxin in patients treated with anti-digoxin antigen binding fragments: a model for future? Clin Chem 1998; 44:1883-5.
74. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit 1996; 18:65-72.
75. Crossey MJ, Dasgupta A. Effects of digoxin-like immunoreactive substances and digoxin FAB antibodies on new digoxin microparticle enzyme immunoassay. Ther Drug Monit 1997; 19:185-90.
76. Dasgupta A, Trejo O. Suppression of total digoxin concentration by digoxin-like immunoreactive substances in the MEIA digoxin assay: elimination of interference by monitoring free digoxin concentrations. Am J Clin Pathol 1999; 111:406-10.
77. Christenson RH, Studenberg SD, Beck-Davis SS, Sedor FA. Digoxin-like immunoreactivity eliminated from serum by centrifugal ultrafiltration before fluorescence polarization immunoassay of digoxin. Clin Chem 1987; 33: 606-8.
78. Steimer W, Muller C, Eber B. Digoxin assays: frequent substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002; 48:507-16.
79. Dasgupta A, Biddle D, Wells A, Datta P. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement; elimination of interference using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentrations. Am J Clin Pathol 2000; 114:174-9.
80. Wahed A, Dasgupta A. Positive and negative in vitro interference of Chinese medicine Danshen in serum digoxin measurement: elimination of interference by monitoring free digoxin concentrations. Am J Clin Pathol 2001; 116: 403-8.
81. Liu H, Montoya JL, Forman LJ, Eggers CM, Barham CF, Delgado M. Determination of free valproic acid: evaluation of the centrifree system and comparison between high performance liquid chromatography and enzyme immunoassay. Ther Drug Monit 1992; 14:513-21.
82. Dasgupta A, Bard D, Pro S, Blackwell, W. Effect of storing serum specimens at 4°C on add-on request for free drug concentration [abstract]. Clin Chem 1995; 41 (Suppl):S117.